Hiraki S, Ohnoshi T, Kishimoto N, Mori K, Nishii K, Yonei T, Yamashita H, Kimura I
Gan To Kagaku Ryoho. 1986 Apr;13(4 Pt 2):1208-13.
The response to cancer chemotherapy varies from patient to patient with the same histologic type of tumor. However, anticancer drugs are considerably toxic to the patient, and it is therefore very important to have an accurate knowledge of the sensitivity of anticancer drugs against an individual patient's tumor in establishing successful chemotherapy. We have investigated the sensitivity testing of anticancer drugs using the human tumor clonogenic assay since 1980. Specimens were obtained by aspiration of ascites, pleural effusions and bone marrow and by biopsy of primary and metastatic tumors. Drugs tested in the present study were adriamycin, aclarubicin, THP-adriamycin, mitoxantrone, 40497s (an active compound derived from ifosfamide), mitomycin C, cisplatinum and methotrexate. One hundred and fifty-two specimens were obtained from cancer patients and tested for their drug sensitivity using the assay. Of the 152 specimens, 63 (41%) formed more than 30 colonies in control plates and could be used to evaluate drug sensitivity. Of these, 45 instances were evaluable for examination in an in vitro-in vivo association, and 42 (93%) showed a correlation between in vitro sensitivity and clinical response. In summary, the results indicated that the human tumor clonogenic assay was an excellent technique for testing the in vitro sensitivity of anticancer drugs. However, technical developments yielding higher colony efficiency would be required to facilitate practical use of the assay.
对于组织学类型相同的肿瘤患者，其对癌症化疗的反应因人而异。然而，抗癌药物对患者具有相当大的毒性，因此在制定成功的化疗方案时，准确了解抗癌药物对个体患者肿瘤的敏感性非常重要。自1980年以来，我们一直使用人肿瘤克隆形成试验来研究抗癌药物的敏感性测试。标本通过抽取腹水、胸水和骨髓以及对原发性和转移性肿瘤进行活检获得。本研究中测试的药物有阿霉素、阿柔比星、吡柔比星、米托蒽醌、40497s（异环磷酰胺的活性化合物）、丝裂霉素C、顺铂和甲氨蝶呤。从癌症患者身上获取了152个标本，并使用该试验检测其药物敏感性。在这152个标本中，有63个（41%）在对照平板上形成了30多个集落，可用于评估药物敏感性。其中，有45例可用于体外-体内相关性检测，42例（93%）显示体外敏感性与临床反应之间存在相关性。总之，结果表明人肿瘤克隆形成试验是检测抗癌药物体外敏感性的一项优秀技术。然而，需要技术改进以提高集落效率，以便于该试验的实际应用。
